Figure 10.
Viability assay results for the three HER2-negative cell lines (a) U-87 MG (human brain cancer); (b) SK-MES-1 (human lung cancer); and (c) MDA-MB-231 (human breast cancer). These cells were incubated with the indicated doses of (ZHER2:4)2DCS-MMAE, 500 nM MMAE, and 500 nM (ZHER2:4)2DCS. Cell viability was assessed after 72, 96, and 120 h incubation. The error bars show the standard deviation.